In lab dishes, curcumin and four other plant compounds stopped many fibrosarcoma cells from dividing; healthy muscle cells were less affected

What the research found

Study (cell lines and wax-moth larvae, not a human cancer trial). ScienceDaily carried the Wroclaw Medical University account on 8 October 2026. Julita Kulbacka and colleagues tested curcumin, berberine, biochanin A, cucurbitacin E, and CAPE from propolis on fibrosarcoma cells and on healthy muscle cells. All five cut cancer-cell ATP by about 83 to 92 percent, against about 23 to 73 percent in the healthy muscle cells. Curcumin raised the share of senescent, non-dividing fibrosarcoma cells from about 16.5 percent to more than 75 percent. The other four each pushed that share above 66 percent. Berberine, cucurbitacin E, and CAPE increased a mitophagy marker in the cancer cells, which the authors read as an overwhelmed cleanup response rather than protection. In greater wax moth larvae, curcumin and berberine were the best tolerated. CAPE and cucurbitacin E were tied to higher mortality, and biochanin A was the most toxic of the five. Kulbacka said the work does not show these compounds can treat sarcomas, and that dosing and delivery are untested in people. Sarcomas are described as under 1 percent of adult cancers and as more than 100 subtypes. Educational notes. This is not medical advice, not a cancer treatment, and not a reason to take curcumin or berberine instead of oncology care. Laboratory activity is weakly evidenced as a human therapy.

Evidence level: Human study. A study in people, but an association isn't proof of cause.

Read the original at Wroclaw Medical University